Key points are not available for this paper at this time.
8024 Background: Neoadjuvant immunotherapy and chemotherapy provide more surgical opportunities and survival benefits to potentially resectable locally advanced NSCLC remains unclear. Herein, we initiated a phase II study to evaluate the feasibility of neoadjuvant immunotherapy and chemotherapy in stage IIIA/IIIB NSCLC. We report the the updated analysis of the study. Methods: Patients (pts) with stage IIIA/IIIB EGFR/ALK/ROS wild-type NSCLC received 2 cycles of neoadjuvantchemoimmunotherapy (PD-1 inhibitor TIS, nab-paclitaxel, and cisplatin/carboplatin) and were reassessed for surgery.Thereafter, pts underwent surgery within 6 weeks and continued 2 cycles of TIS plus chemotherapy, followed by up to 15 cycles of TIS monotherapy. The primary endpoint was R0 resection rate, and secondary endpoints included major pathologic response (MPR), pathologic complete response (pCR), 1/2-year EFS rate, and overall survival, etc. Results: From Jan 2021 to Sep 2023, 33 pts were enrolled; 19 (58% ) pts with IIIA and 14 (42%) pts with IIIB disease, As of 14 Sep 2023, 27 pts completed neoadjuvant and 25 pts underwent resection. and 6 pts were on neoadjuvant. 2 pts downstaging had obvious downstaging after neoadjuvant treatment and were unwilling to surgery. 24 of 25 pts (96%) underwent successful R0 resection (Table). Of 25 pts who underwent resection,8 (32%) pts achieved pCR, 15 (60%) pts achieved pathologic response rate.Of the 7 pts who achieved MPR, 5 had only about 1% viable tumor cells in the resection specimen. The overall response rate (ORR) and disease control rate (DCR) were 88% (22/25) and 100 % (25/25), respectively. The clinical downstaging occurred in 22 of 25 pts (88%).The pathological downstaging occurred in 23 of 25 pts (92%).And The 1-year EFS rate 82.3% (95%CI 58.3-93.2), 2-year EFS rate 76.4% (95%CI 51.1-89.8). Conclusions: Neoadjuvant TIS plus chemotherapy increased surgical opportunities and survival benefits in potentially resectable locally advanced stage IIIA/IIIB NSCLC. Table: see text
Wang et al. (Sat,) studied this question.